Enumeral Biomedical's Series A - III Round

Enumeral Biomedical raised a round of funding on May 07, 2014. Investors include Harris & Harris Group.

Enumeral Biomedical engages in the discovery of native human monoclonal antibodies for use in the diagnosis and treatment of infectious, autoimmune and inflammatory diseases. The company's microengrav…

Articles about Enumeral Biomedical's Series A - III Round: